Gilead Sciences (GILD) Stock Forecast & Price Target

Compare

13,709 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GILD Analyst Ratings

Strong Buy

16 Buy

3 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Gilead

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GILD Stock 12 Month Forecast

Average Price Target

$135.00

▲(8.00% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is $135.00 with a high forecast of $150.00 and a low forecast of $105.00. The average price target represents a 8.00% change from the last price of $125.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"85":"$85","118":"$118","151":"$151","101.5":"$101.5","134.5":"$134.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":150,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$150.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$135.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$105.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[85,101.5,118,134.5,151],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,119.79,122.11384615384615,124.43769230769232,126.76153846153846,129.0853846153846,131.40923076923076,133.73307692307694,136.05692307692308,138.38076923076923,140.70461538461538,143.02846153846153,145.3523076923077,147.67615384615385,{"y":150,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,119.79,120.96000000000001,122.13000000000001,123.30000000000001,124.47,125.64,126.81,127.98,129.15,130.32,131.49,132.66,133.83,{"y":135,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,119.79,118.6523076923077,117.5146153846154,116.37692307692308,115.23923076923077,114.10153846153847,112.96384615384616,111.82615384615384,110.68846153846154,109.55076923076923,108.41307692307693,107.27538461538461,106.1376923076923,{"y":105,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":86.92,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.45,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.18,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.94,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.73,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 71,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.93,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.79,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$150.00

Average Price Target$135.00

Lowest Price Target$105.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Courtney Breen

Bernstein

$135

Buy

8.00%

Upside

Reiterated

11/26/25

Gilead Sciences (GILD) Gets a Buy from Bernstein

Evan Seigerman

BMO Capital

$135

Buy

8.00%

Upside

Reiterated

11/24/25

Gilead Sciences: Promising Growth and Diversification Beyond HIV with Oncology Expansion

Asthika Goonewardene

Truist Financial

$145→$140

Buy

12.00%

Upside

Reiterated

11/24/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Salim Syed

Mizuho Securities

$131→$140

Buy

12.00%

Upside

Reiterated

11/20/25

Gilead price target raised to $140 from $131 at MizuhoGilead price target raised to $140 from $131 at Mizuho

Geoff Meacham

Citi

$135

Buy

8.00%

Upside

Reiterated

11/14/25

Citi Keeps Their Buy Rating on Gilead Sciences (GILD)

Joseph Stringer

Needham

$133→$140

Buy

12.00%

Upside

Reiterated

11/13/25

Gilead Sciences' Strategic Advancements in HIV Treatment Bolster Buy Rating and Future Revenue Prospects

Louise Chen

Scotiabank

$140

Buy

12.00%

Upside

Initiated

11/12/25

Gilead initiated with an Outperform at ScotiabankGilead initiated with an Outperform at Scotiabank

Michael Okunewitch

Maxim Group

―

Hold

―

Reiterated

11/04/25

Gilead Sciences: Balanced Hold Rating Amidst Strong HIV Performance and Modest Diversification Challenges

Mohit Bansal

Wells Fargo

$140→$145

Buy

16.00%

Upside

Reiterated

10/31/25

Gilead price target raised to $145 from $140 at Wells FargoGilead price target raised to $145 from $140 at Wells Fargo

Terence Flynn

Morgan Stanley

$143→$147

Buy

17.60%

Upside

Reiterated

10/31/25

Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM), Gilead Sciences (NASDAQ: GILD) and Agios Pharma (NASDAQ: AGIO)

Carter Gould

Cantor Fitzgerald

$135

Buy

8.00%

Upside

Reiterated

10/31/25

Analysts Are Bullish on Top Healthcare Stocks: Cabaletta Bio (CABA), Gilead Sciences (GILD)We maintain our Overweight rating and our price target of $135.

Chris Schott

J.P. Morgan

$145→$150

Buy

20.00%

Upside

Reiterated

10/31/25

Gilead price target raised to $150 from $145 at JPMorganGilead price target raised to $150 from $145 at JPMorgan

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

10/31/25

Evercore ISI Sticks to Their Buy Rating for Gilead Sciences (GILD)

Matthew Biegler

Oppenheimer

$128

Buy

2.40%

Upside

Reiterated

10/31/25

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and Option Care Health (NASDAQ: OPCH)

David Dai

UBS

$112

Hold

-10.40%

Downside

Reiterated

10/31/25

Gilead Sciences (GILD) Gets a Hold from UBS

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Courtney Breen

Bernstein

$135

Buy

8.00%

Upside

Reiterated

11/26/25

Gilead Sciences (GILD) Gets a Buy from Bernstein

Evan Seigerman

BMO Capital

$135

Buy

8.00%

Upside

Reiterated

11/24/25

Gilead Sciences: Promising Growth and Diversification Beyond HIV with Oncology Expansion

Asthika Goonewardene

Truist Financial

$145→$140

Buy

12.00%

Upside

Reiterated

11/24/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Salim Syed

Mizuho Securities

$131→$140

Buy

12.00%

Upside

Reiterated

11/20/25

Gilead price target raised to $140 from $131 at MizuhoGilead price target raised to $140 from $131 at Mizuho

Geoff Meacham

Citi

$135

Buy

8.00%

Upside

Reiterated

11/14/25

Citi Keeps Their Buy Rating on Gilead Sciences (GILD)

Joseph Stringer

Needham

$133→$140

Buy

12.00%

Upside

Reiterated

11/13/25

Gilead Sciences' Strategic Advancements in HIV Treatment Bolster Buy Rating and Future Revenue Prospects

Louise Chen

Scotiabank

$140

Buy

12.00%

Upside

Initiated

11/12/25

Gilead initiated with an Outperform at ScotiabankGilead initiated with an Outperform at Scotiabank

Michael Okunewitch

Maxim Group

―

Hold

―

Reiterated

11/04/25

Gilead Sciences: Balanced Hold Rating Amidst Strong HIV Performance and Modest Diversification Challenges

Mohit Bansal

Wells Fargo

$140→$145

Buy

16.00%

Upside

Reiterated

10/31/25

Gilead price target raised to $145 from $140 at Wells FargoGilead price target raised to $145 from $140 at Wells Fargo

Terence Flynn

Morgan Stanley

$143→$147

Buy

17.60%

Upside

Reiterated

10/31/25

Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM), Gilead Sciences (NASDAQ: GILD) and Agios Pharma (NASDAQ: AGIO)

Carter Gould

Cantor Fitzgerald

$135

Buy

8.00%

Upside

Reiterated

10/31/25

Analysts Are Bullish on Top Healthcare Stocks: Cabaletta Bio (CABA), Gilead Sciences (GILD)We maintain our Overweight rating and our price target of $135.

Chris Schott

J.P. Morgan

$145→$150

Buy

20.00%

Upside

Reiterated

10/31/25

Gilead price target raised to $150 from $145 at JPMorganGilead price target raised to $150 from $145 at JPMorgan

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

10/31/25

Evercore ISI Sticks to Their Buy Rating for Gilead Sciences (GILD)

Matthew Biegler

Oppenheimer

$128

Buy

2.40%

Upside

Reiterated

10/31/25

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and Option Care Health (NASDAQ: OPCH)

David Dai

UBS

$112

Hold

-10.40%

Downside

Reiterated

10/31/25

Gilead Sciences (GILD) Gets a Hold from UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

1 Month

xxx

Success Rate

21/32 ratings generated profit

Average Return

+2.75%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 65.63% of your transactions generating a profit, with an average return of +2.75% per trade.

3 Months

xxx

Success Rate

24/32 ratings generated profit

Average Return

+5.44%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +5.44% per trade.

1 Year

Chris SchottJ.P. Morgan

Success Rate

18/20 ratings generated profit

Average Return

+25.21%

reiterated a buy rating last month

Copying Chris Schott's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +25.21% per trade.

2 Years

xxx

Success Rate

20/20 ratings generated profit

Average Return

+39.24%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +39.24% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GILD Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GILD has received 46 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. GILD average Analyst price target in the past 3 months is 135.00.

Each month's total comprises the sum of three months' worth of ratings.

GILD Financial Forecast

GILD Earnings Forecast

Next quarter’s earnings estimate for GILD is $1.87 with a range of $1.75 to $2.08. The previous quarter’s EPS was $2.47. GILD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Sales Forecast

Next quarter’s sales forecast for GILD is $7.65B with a range of $6.95B to $8.20B. The previous quarter’s sales results were $7.78B. GILD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year GILD has Performed in-line its overall industry.

GILD Stock Forecast FAQ

What is GILD’s average 12-month price target, according to analysts?

Based on analyst ratings, Gilead Sciences’s 12-month average price target is 135.00.

What is GILD’s upside potential, based on the analysts’ average price target?

Gilead Sciences has 8.00% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GILD a Buy, Sell or Hold?

Gilead Sciences has a consensus rating of Strong Buy which is based on 16 buy ratings, 3 hold ratings and 0 sell ratings.

What is Gilead Sciences’s price target?

The average price target for Gilead Sciences is 135.00. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $150.00 ,the lowest forecast is $105.00. The average price target represents 8.00% Increase from the current price of $125.

What do analysts say about Gilead Sciences?

Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of GILD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Gilead Sciences (GILD) Stock Forecast & Price Target

GILD Analyst Ratings

GILD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Gilead Sciences

GILD Analyst Recommendation Trends

GILD Financial Forecast

GILD Earnings Forecast

GILD Sales Forecast

GILD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts